[go: up one dir, main page]

BR0316364A - Combinação de terapia do câncer com um composto anticâncer ativado com gst e uma outra terapia anticâncer - Google Patents

Combinação de terapia do câncer com um composto anticâncer ativado com gst e uma outra terapia anticâncer

Info

Publication number
BR0316364A
BR0316364A BR0316364-4A BR0316364A BR0316364A BR 0316364 A BR0316364 A BR 0316364A BR 0316364 A BR0316364 A BR 0316364A BR 0316364 A BR0316364 A BR 0316364A
Authority
BR
Brazil
Prior art keywords
gst
therapy
anticancer
compound
activated
Prior art date
Application number
BR0316364-4A
Other languages
English (en)
Inventor
Hua Xu
Gail L Brown
Steven R Schow
James G Keck
Original Assignee
Telik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telik Inc filed Critical Telik Inc
Publication of BR0316364A publication Critical patent/BR0316364A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"COMBINAçãO DE TERAPIA DO CâNCER COM UM COMPOSTO ANTICâNCER ATIVADO COM GST E UMA OUTRA TERAPIA ANTICâNCER". A presente invenção refere-se a um método de combinação de terapia do câncer em um mamífero, especialmente um ser humano, por administração de uma quantidade terapeuticamente eficaz de um composto anticâncer ativado com GST e uma dose terapeuticamente eficaz de uma outra terapia anticâncer. Composições farmacêuticas, produtos e kits para o método. O uso de um composto anticâncer ativado com GST na produção de um medicamento para o método. Um método de potencializar uma terapia anticâncer em um mamífero, especialmente um ser humano, compreendendo a administração de uma quantidade terapeuticamente eficaz de um composto anticâncer ativado com GST ao mamífero em tratamento com a terapia anticâncer. O uso de um composto anticâncer ativado com GST na produção de um medicamento para o método. O composto anticâncer ativado com GST é de preferência um composto da Patente U.S. n<0> 5.556.942, e mais preferivelmente TLK286, especialmente como o sal de cloridrato.
BR0316364-4A 2002-11-15 2003-11-14 Combinação de terapia do câncer com um composto anticâncer ativado com gst e uma outra terapia anticâncer BR0316364A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42698302P 2002-11-15 2002-11-15
PCT/US2003/036209 WO2004045593A2 (en) 2002-11-15 2003-11-14 Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy

Publications (1)

Publication Number Publication Date
BR0316364A true BR0316364A (pt) 2005-10-04

Family

ID=32326463

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316364-4A BR0316364A (pt) 2002-11-15 2003-11-14 Combinação de terapia do câncer com um composto anticâncer ativado com gst e uma outra terapia anticâncer

Country Status (12)

Country Link
US (2) US20040138140A1 (pt)
EP (1) EP1562564A2 (pt)
JP (2) JP2006508980A (pt)
KR (1) KR20050075018A (pt)
CN (2) CN100508961C (pt)
AR (1) AR042051A1 (pt)
AU (2) AU2003290805A1 (pt)
BR (1) BR0316364A (pt)
CA (1) CA2505377A1 (pt)
MX (1) MXPA05005200A (pt)
TW (1) TWI323662B (pt)
WO (1) WO2004045593A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
TW200538149A (en) * 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
AU2005333515B2 (en) * 2004-07-09 2012-05-10 Arizona Board Of Regents, Acting On Behalf Of The University Of Arizona Wortmannin analogs and methods of using same in combination with chemotherapeutic agents
EP1833978B1 (en) * 2005-01-06 2008-10-08 Telik, Inc. Tripeptide and tetrapeptide thioethers
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
CN101809024A (zh) * 2007-07-16 2010-08-18 铂雅制药公司 吡铂的口服制剂
US8877803B2 (en) 2007-09-10 2014-11-04 Boston Biomedical, Inc. Stat3 pathway inhibitors and cancer stem cell inhibitors
US20110053879A1 (en) * 2008-02-08 2011-03-03 Poniard Pharmaceuticals, Inc. Picoplatin and amrubicin to treat lung cancer
CA2719853A1 (en) * 2008-03-25 2009-10-01 Paloma Pharmaceuticals, Inc. Methods of treating fibrotic disorders
WO2010086964A1 (ja) * 2009-01-28 2010-08-05 株式会社 静岡カフェイン工業所 がん治療のための併用療法
EP2425830A1 (en) * 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistic drug combination for the treatment of cancer
WO2012075211A2 (en) * 2010-12-01 2012-06-07 Niiki Pharma Inc. Combination therapy with a gallium complex
WO2012112791A1 (en) * 2011-02-16 2012-08-23 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
US20120251496A1 (en) * 2011-03-31 2012-10-04 Telik, Inc. Ezatiostat for treating multiple myeloma
CA2908380A1 (en) 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer
US20170080093A1 (en) * 2013-10-22 2017-03-23 Tyme, Inc. Tyrosine Derivatives And Compositions Comprising Them
RU2704811C2 (ru) * 2014-07-17 2019-10-31 БайоКьюрити Фармасьютикалз Инк. Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства
US11389536B2 (en) 2015-07-17 2022-07-19 BioCurity Pharmaceuticals Inc. Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
BR112019011033A2 (pt) * 2016-11-30 2019-10-15 Tyme Inc composição, método para reduzir a proliferação celular em um indivíduo, método para tratar câncer em um indivíduo e kit
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599903A (en) * 1992-04-03 1997-02-04 Terrapin Technologies, Inc. Glutathione analogs and paralog panels comprising glutathione mimics
US5556942A (en) * 1991-04-29 1996-09-17 Terrapin Technologies, Inc. Glutathione S-transferase-activated compounds
US5545621A (en) * 1991-04-29 1996-08-13 Terrapin Technologies, Inc. Glutathione S-transferase-activated compounds
US5955432A (en) * 1992-04-03 1999-09-21 Terrapin Technologies, Inc. Metabolic effects of certain glutathione analogs
US5767147A (en) * 1995-04-21 1998-06-16 The Regents Of The University Of California Inhibition of glutathione transferase by haloenol lactones
DK0831877T3 (da) * 1995-06-07 2005-02-14 Telik Inc Metabolske virkninger af visse glutathionanaloge
US5880097A (en) * 1996-01-04 1999-03-09 Terrapin Techologies, Inc. Tethered prodrugs
US20030073837A1 (en) * 1998-12-31 2003-04-17 Langecker Peter J. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
US6281223B1 (en) * 1999-04-13 2001-08-28 Supergen, Inc. Radioenhanced camptothecin derivative cancer treatments
GB9909925D0 (en) * 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
CA2400197A1 (en) * 2000-02-17 2001-08-23 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
JP2004523517A (ja) * 2000-12-22 2004-08-05 ブリストル−マイヤーズ スクイブ カンパニー 腫瘍増殖および転移を調節するための方法
TW200538149A (en) * 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound

Also Published As

Publication number Publication date
US20080159980A1 (en) 2008-07-03
CA2505377A1 (en) 2004-06-03
EP1562564A2 (en) 2005-08-17
AR042051A1 (es) 2005-06-08
CN101590229B (zh) 2012-12-05
CN101590229A (zh) 2009-12-02
AU2010200483A1 (en) 2010-03-04
CN100508961C (zh) 2009-07-08
KR20050075018A (ko) 2005-07-19
WO2004045593A2 (en) 2004-06-03
TW200412933A (en) 2004-08-01
TWI323662B (en) 2010-04-21
JP2006508980A (ja) 2006-03-16
WO2004045593A3 (en) 2004-08-12
AU2003290805A1 (en) 2004-06-15
JP2010265305A (ja) 2010-11-25
US20040138140A1 (en) 2004-07-15
MXPA05005200A (es) 2005-08-18
CN1711076A (zh) 2005-12-21

Similar Documents

Publication Publication Date Title
BR0316364A (pt) Combinação de terapia do câncer com um composto anticâncer ativado com gst e uma outra terapia anticâncer
BRPI0511296A (pt) sensibilização à outra terapia anticáncer e/ou melhora de um efeito colateral de outra terapia anticáncer por tratamento com um composto anticáncer ativado por gst
BR0316050A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
BRPI0411451A (pt) formas de dosagens orais de memantina
BR0009647A (pt) Docetaxel em combinação com rhumab her2 para o tratamento de cânceres
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
BRPI0407897A (pt) derivados de cianopiridina úteis no tratamento de cáncer e outros distúrbios
BRPI0411024A (pt) métodos para induzir a eritropoiese intensificada ou completa em um paciente, para tratar ou prevenir doenças, e para aumentar a produção da eritropoietina na presença de uma citocina em um paciente, uso de um composto, kit, e, composição farmacêutica
BRPI0416656A (pt) compostos de pirrolopirimidina úteis no tratamento do cáncer
CA2531862A1 (en) Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BRPI0518266A2 (pt) medicamento oral de libertaÇço modificada de pelo menos um princÍpio ativo sob a forma multimicrocapsular
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BRPI0409427A (pt) composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo
BRPI0412919A (pt) combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos
BRPI0409796A (pt) uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina
PA8627601A1 (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-ilo]-(4-bromo-3-metil-5-propoxi-tiofen-2-ilo)-metanona hidrocloruro como un inhibidor de triptasa de mastocitos
HK1071310A1 (en) Combination therapy for the treatment of cancer
AR065582A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
BRPI0409818A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
DE602007012904D1 (de) Neue 2&#39;,3&#39;-methylidenacetyladenosine prodrugs zur
BRPI0409878A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BR112012020377A2 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2280 DE 16/09/2014.